Company Filing History:
Years Active: 2022-2023
Title: Martin Preyer: Innovator in Cancer Treatment
Introduction
Martin Preyer is a notable inventor based in Somerville, MA (US), recognized for his contributions to cancer treatment technologies. He holds 2 patents that showcase his innovative approach to addressing complex medical challenges.
Latest Patents
One of his latest patents is the Twin Immune Cell Engager (TWICE), which is a kit or composition designed for treating cancer. This invention comprises a first and second component, each containing a targeting moiety that binds to tumor antigens expressed by cancer cells or antigens expressed by non-cancer cells in the tumor microenvironment. The components are engineered to enhance immune cell binding activity, thereby improving the therapeutic potential against cancer.
Another significant patent is the Bispecific Antibody Platform, which provides a technology for generating properly paired bispecific antibodies. This platform includes modifications to the Fc region and Fab arms of the antibodies to prevent mispairing of light chains and enhance their efficacy. These innovations represent a significant advancement in the field of immunotherapy.
Career Highlights
Throughout his career, Martin Preyer has worked with prominent companies in the biotechnology sector, including Revitope Limited and Biogen MA Inc. His work has focused on developing cutting-edge solutions for cancer treatment, contributing to the advancement of medical science.
Collaborations
Martin has collaborated with talented professionals in the field, including Allison Colthart and Pamela Weinstein. These partnerships have played a crucial role in the development of his innovative technologies.
Conclusion
Martin Preyer's work in cancer treatment through his patents exemplifies the impact of innovation in medicine. His contributions continue to pave the way for new therapeutic strategies that can improve patient outcomes.